Lineage Cell Therapeutics, Inc. (LCTX) is a Biotechnology company in the Healthcare sector, currently trading at $1.59. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: LCTX trades at a trailing Price-to-Earnings (P/E) of -5.6 (S&P 500 average ~25).
Financials: revenue is $15M, +6.8%/yr average growth. Net income is $64M (loss), growing at -69.9%/yr. Net profit margin is -436.5% (negative). Gross margin is 94.2% (-0.8 pp trend).
Balance sheet: total debt is $2M against $45M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 5.2 (strong liquidity). Debt-to-assets is 2.1%. Total assets: $113M.
Analyst outlook: 5 / 5 analysts rate LCTX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
